Author:
Tsang Erica S.,Davies Janine M.,Loree Jonathan M.,Lim Howard J.,Renouf Daniel J.,Gill Sharlene
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference29 articles.
1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016
2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
3. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial;El-Khoueiry;Lancet,2017
4. Nivolumab (nivo) in sorafenib (sor)-naive and -experience pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study;Crocenzi;J Clin Oncol,2017
5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017